Posted 26 May 2022 | By
In Focus: US
- Lawmakers grill U.S. FDA on response to Abbott baby formula safety (Reuters) (NYTimes)
- The next U.S. abortion battle is over pills, and it’s already begun (Reuters)
- Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors (KHN)
- A no good, very bad week for the FDA (STAT)
- Eli Lilly set to invest $2.1B in home state manufacturing boost (Endpoints) (PharmaPhorum)
- McKesson, Walgreens, Drug Distributors Dodge Price-Fixing Claims (Bloomberg Law)
- US sees spike in Paxlovid usage as Merck’s molnupiravir and AstraZeneca’s Evusheld are slower off the shelf (Endpoints)
- NIH’s new, independent breakthrough drug accelerator ARPA-H gets its first employee (Endpoints)
- CMS turning attention to hospitals with Covid outbreaks (Politico)
In Focus: International
- Cancer treatments may benefit from lessons of pandemic set-backs -AstraZeneca executive (Reuters)
- Medtronic posts downbeat results on supply chain issues, China hit (Reuters) (MedtechDive)
- NICE recommends Sanofi and Regeneron’s Libtayo for advanced CSCC (PMLive)
- Vaccines hold potential to curb antibiotic resistance (FT)
- Diagnostic tests a crucial tool in fight against antibiotic resistance (FT)
- Happy IVDR day! (MedicalDevicesLegal)
Pharma & Biotech
- Flagship’s latest startup launches with bold claim: the discovery of thousands of new human proteins (STAT) (Endpoints)
- Taking another shot at mRNA glory, CureVac inks oncology pact while keeping up with Covid work (Endpoints)
- Bristol’s Abecma, Amgen’s Lumakras headline record-setting oncology launch class as costs continue to balloon: IQVIA (Fierce)
- Former Editas CEO Katrine Bosley goes the VC route, joining early-stage investor (Endpoints)
- Covaxin clinical trials to resume in the US as FDA lifts halt (Live Mint)
- Avadel’s shares crumble as narcolepsy drug delayed yet again, this time on patent issue (Fierce)
- This time around, Lyrica’s inventor is developing his Northwestern discoveries at his own biotech (Endpoints)
- Pfizer and CDMOs ramp up Paxlovid manufacturing with Kalamazoo plant expansion leading the way (Endpoints)
- PK Evaluation In Pregnancy: Can HIV Show A Way Forward? (Pink Sheet)
- Zydus Pivots To Multivariant COVID-19 Vaccine, Looks To Revlimid Opportunity (Scrip)
Medtech
- Baxter raises forecasts for Hillrom synergies, allaying concerns over $10.5B takeover (MedtechDive)
- How a Dexcom-Insulet combination would shake up the diabetes treatment industry (MedtechDive)
- FDA’s QMSR: 3 Experts Read Draft Rule Comments So You Don’t Have To. Here’s What They Saw (MedtechInsight)
- Pew Responds To Draft Legislation Creating Regulatory Oversight Of Lab Developed Diagnostics (MedtechInsight)
- Proposed LDT regulations has diagnostics industry, consumer groups at odds (MedtechDive)
- Roche unveils three new monkeypox tests as cases rise (Endpoints)
- Abbott Medical Recalls Dragonfly OpStar Imaging Catheter for Potential Loose Catheter Marker Band That May Cause Patient Harm (FDA)
Government, Regulatory & Legal
- Biotech Founder Arrested in Murder-for-Hire Scheme (WSJ)
- Generic Distributors Slip Indirect Reseller Price-Fixing Claims (Law360)
Regulatory Recon is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe.
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
© 2022 Regulatory Affairs Professionals Society.